Drugs / PCV24
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07025876 | Nov 2023 → Jun 2024 | streptococcal pneumonia | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07543198 | Jun 2025 → Feb 2026 | pneumococcal infection | Sinovac Life Sciences Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07035054 | Apr → Nov 2024 | streptococcal pneumonia | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-01-05 | CanSino Biologics Inc. | Regulatory CanSinoBIO Advances Pneumococcal Vaccine Portfolio as PCV24 Receives Clinical Trial Approval cansinotech.com ↗
CanSino Biologics Inc.(CanSinoBIO) announced today that its 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid) (the “PCV24”) has received clinical trial approval from the National Medical Products Administration (NMPA). |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-05-25 | CanSino Biologics Inc. | CanSinoBIO Advances Pneumococcal Disease Prevention Strategy with Initiation of Phase I/II Trial for PCV24 cansinotech.com ↗ |
| 2026-01-05 | CanSino Biologics Inc. | CanSinoBIO Advances Pneumococcal Vaccine Portfolio as PCV24 Receives Clinical Trial Approval cansinotech.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PCV24 | “PCV24 (low-dose 1) developed by Shanghai Ruizhou Biotechnology Co., Ltd. and Changchun Ruizhou Biopharmaceutical Co., Ltd. is a liquid formulation.” NCT07035054 ↗ |
| Known as | 24-valent Pneumococcal Polysaccharide Conjugate Vaccine | “A phase Ib/II clinical trial of the study of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV24) developed by Sinovac Life Science Co., Ltd (Sinovac) will be...” NCT07543198 ↗ |
| Modality | Vaccine | “24-valent pneumococcal polysaccharide conjugate vaccine” NCT07025876 ↗ |